NASDAQ · CORT
Healthcare · Biotechnology
$81.12
Down-$4.83 (-5.62%)
Updated Nov 2, 2026, 10:10 AM
SID Score
4.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CORT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CORT closed at $81.12 after 20 trading sessions, down 33.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $85.00 | $85.305 | $80.28 | $81.12 | 1.43M |
| Oct 29, 2026 | $86.07 | $88.01 | $85.21 | $85.95 | 1.19M |
| Oct 28, 2026 | $86.43 | $88.59 | $86.00 | $86.28 | 1.05M |
| Oct 27, 2026 | $85.31 | $87.97 | $84.91 | $87.59 | 925.52K |
| Oct 26, 2026 | $86.10 | $91.78 | $85.86 | $87.125 | 1.87M |
| Oct 23, 2026 | $106.05 | $106.0925 | $84.13 | $85.86 | 3.1M |
| Oct 22, 2026 | $115.16 | $115.73 | $107.3269 | $107.50 | 809.88K |
| Oct 21, 2026 | $116.45 | $118.42 | $116.10 | $116.28 | 516.77K |
| Oct 20, 2026 | $112.60 | $117.135 | $111.955 | $116.45 | 549.57K |
| Oct 19, 2026 | $111.70 | $113.09 | $110.50 | $112.10 | 392.85K |
| Oct 16, 2026 | $113.17 | $113.635 | $107.7902 | $110.16 | 849.97K |
| Oct 15, 2026 | $116.31 | $117.4792 | $113.0201 | $113.37 | 668.52K |
| Oct 14, 2026 | $117.94 | $122.2099 | $115.95 | $116.23 | 691.96K |
| Oct 13, 2026 | $121.83 | $122.8087 | $117.4201 | $117.80 | 556.29K |
| Oct 12, 2026 | $121.24 | $122.09 | $119.28 | $121.19 | 497.74K |
| Oct 9, 2026 | $118.00 | $122.34 | $117.41 | $121.19 | 624.21K |
| Oct 8, 2026 | $118.56 | $119.155 | $115.80 | $118.54 | 496.67K |
| Oct 7, 2026 | $119.00 | $121.9999 | $117.23 | $119.60 | 634.88K |
| Oct 6, 2026 | $122.20 | $122.5399 | $115.11 | $119.57 | 790.54K |
| Oct 5, 2026 | $115.59 | $122.81 | $115.50 | $122.03 | 1M |
The latest Smart Investors Daily articles mentioning CORT.
Company
Market Activity
Research & News
CORT research
Company profile and research snapshot.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| Jul 30, 2026 | Piper Sandler | Overweight | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 27, 2026
REDWOOD CITY, Calif., October 27, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Yahoo · Oct 26, 2026
Corcept Therapeutics recently reported Part A results from its Phase 2 BELLA trial. In 95 women with platinum-resistant ovarian cancer, Lifyorli plus nab-paclitaxel and bevacizumab showed longer median PFS and higher ORR than Lifyorli plus nab-paclitaxel and nab-paclitaxel alone in the separate ROSELLA study, with no new safety signals. An important nuance for Corcept Therapeutics is that outcomes in BELLA appeared stronger in bevacizumab-naive patients. This suggests that prior treatment...
Benzinga · Oct 26, 2026
Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.
Yahoo · Oct 26, 2026
REDWOOD CITY, Calif., October 26, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company’s Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CORT.
